Amneal Pharmaceuticals (AMRX) Research & Development (2017 - 2026)

Amneal Pharmaceuticals has reported Research & Development for 10 years, with the latest figure at $39.0 million in Q2 2026.

• On a quarterly basis, Research & Development fell 18.65% year-over-year to $39.0 million in Q2 2026; TTM through Jun 2026 was $175.6 million, a 13.67% decrease from a year earlier, with the FY2025 full-year figure at $186.2 million, down 2.38% from the prior year.
• Research & Development was $39.0 million for Q2 2026 at Amneal Pharmaceuticals, up from $38.4 million in the prior quarter.
• The five-year high for Research & Development was $63.4 million in Q3 2025, with the low at $34.8 million in Q4 2025.
• Average Research & Development over 5 years is $45.2 million, with a median of $41.6 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Research & Development jumped 47.67% in 2024, then plunged 35.84% in 2025.
• Over 5 years, Research & Development stood at $41.9 million in 2022, then climbed by 9.97% to $46.1 million in 2023, then climbed by 17.75% to $54.3 million in 2024, then plunged by 35.84% to $34.8 million in 2025, then increased by 12.06% to $39.0 million in 2026.
• The last three Research & Development figures came in at $39.0 million (Q2 2026), $38.4 million (Q1 2026), and $34.8 million (Q4 2025), per Business Quant data.